The Long-Term Effect of Dienogest on Bone Mineral Density After Surgical Treatment of Endometrioma
After 3 years of dienogest use post-endometrioma surgery, bone mineral density significantly decreased in the lumbar spine and femur neck, with bone loss predominantly occurring in the first year and no predictive factors identified.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
This retrospective study evaluated changes in bone mineral density (BMD) over 3 years in 44 reproductive-aged women who received dienogest 2 mg/day following laparoscopic endometrioma surgery, with an additional analysis of predictive factors using BMD changes after 1 year in a larger set (160 women with decreased BMD). After 3 years, BMD significantly decreased at both the lumbar spine (−4.4%) and femur neck (−3.6%), with most lumbar spine loss occurring during the first year followed by a more gradual decline. The authors found no associated predictive factors for BMD reduction based on the first-year BMD change analysis, which is a key limitation in identifying who may be at higher risk. This paper is centrally about endometriosis — it examines long-term effects of postoperative dienogest on BMD after surgical treatment of endometrioma.
Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (29)
- Clinical Management of Endometriosis via openalex
- Comparison of long-term use of combined oral contraceptive after gonadotropin-releasing hormone agonist plus add-back therapy versus dienogest to prevent recurrence of ovarian endometrioma after surgery via openalex
- Current Strategies for Endometriosis Management via openalex
- Dienogest and the Risk of Endometriosis Recurrence Following Surgery: A Systematic Review and Meta-analysis via openalex
- Dienogest: A New Therapeutic Agent for the Treatment of Endometriosis via openalex
- Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis—a randomized, double-blind, multicenter, controlled trial via openalex
- Differences in characteristics among 1,000 women with endometriosis based on extent of disease via openalex
- Effects of long-term postoperative dienogest use for treatment of endometriosis on bone mineral density via openalex
- Endometriosis via openalex
- Epidemiology of endometriosis: a large population‐based database study from a healthcare provider with 2 million members via openalex
- Hormone treatment of endometriosis: The estrogenthreshold hypothesis via openalex
- Laparoscopic surgery for endometriosis via openalex
- Ovulation‐Inhibiting Effects of Dienogest in a Randomized, Dose‐Controlled Pharmacodynamic Trial of Healthy Women via openalex
- Prevention of the recurrence of symptom and lesions after conservative surgery for endometriosis via openalex
- Recurrence of ovarian endometrioma after laparoscopic excision via openalex
- Surgery for endometriosis: beyond medical therapies via openalex
- Treatment of endometriosis in different ethnic populations: a meta-analysis of two clinical trials via openalex
- W2101417341 via openalex
- W2045458073 via openalex
- W2901718309 via openalex
- W2021687464 via openalex
- W1997810509 via openalex
- W4211081176 via openalex
- W1523893866 via openalex
- W6612567677 via openalex
- W6636794944 via openalex
- W2137746400 via openalex
- W6733047331 via openalex
- W2132577372 via openalex
Cited by (9)
- Short-term safety of dienogest on bone mineral density in Iranian women with endometriosis: A cross-sectional study 2026
- Results of dienogest treatment and its discontinuation in patients with symptomatic adenomyosis: a prospective cohort study 2025
- Dienogest Therapy Against the Combined Oral Contraceptive Pill in Deep Infiltrating Endometriosis Cases: A Systematic Review and Meta-Analysis 2025
- Efficacy and safety of dienogest in the treatment of deep infiltrating endometriosis: A meta-analysis 2024
- A systematic review and Bayesian analysis of the adverse effects of dienogest 2024
- Proposal for targeted, neo-evolutionary-oriented secondary prevention of early-onset endometriosis and adenomyosis. Part II: medical interventions 2023
- Resolution of the First Ukrainian endometriosis forum “Drug treatment for endometriosis-associated pelvic pain. The quality of a woman’s life” 2023
- Hormonal Therapy in Endometriosis and Adenomyosis: Progestins 2022
- Endometriosis, hormonal therapy and oncological risks 2021
Source provenance
- europepmc
- last seen: 2026-06-11T06:19:48.454388+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-05-13T22:24:55.077982+00:00